From: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
Group
600
300
150
75
37.5
IC50
OCUM-2MD3
85.2 ± 0.9
74.6 ± 1.7
65.4 ± 2.1
51.2 ± 1.4
37.3 ± 2.2
71.2
OCUM-2MD3/L-OHP
72.4 ± 1.5*
52.7 ± 2.6*
43.5 ± 0.8*
26.4 ± 1.5*
9.8 ± 3.2*
235.2